Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

ISSN： 1175-6349

Source： Treatments in Endocrinology, Vol.4, Iss.6, 2005-01, pp. : 361-370

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus

By Hogan Andrew Gaoatswe Gadintshware Lynch Lydia Corrigan Michelle Woods Conor O’Connell Jean O’Shea Donal

Diabetologia, Vol. 57, Iss. 4, 2014-04 ,pp. : 781-784

Springer Publishing Company

Access to resources Recommend Favorite

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy

Current Diabetes Reviews, Vol. 12, Iss. 4, 2016-10 ,pp. : 403-413

Bentham Science Publishers

Access to resources Recommend Favorite

Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus

By Cypryk Katarzyna Vilsbøll Tina Nadel Iwona Smyczynska Joanna Holst Jens Juul Lewinski Andrzej

Gynecological Endocrinology, Vol. 23, Iss. 1, 2007-01 ,pp. : 58-62

Informa Healthcare

Access to resources Recommend Favorite

Potentiation and prolongation of the insulinotropic action of glucagon-like peptide 1 by methyl pyruvate or dimethyl ester of l-glutamic acid in a type 2 diabetes animal model

By Cancelas Jesús Villanueva-Peñacrrillo María Valverde Isabel Malaisse Willy

Endocrine Journal, Vol. 16, Iss. 2, 2001-11 ,pp. : 113-116

Humana Press, Inc

Access to resources Recommend Favorite

Glucagon-like Peptide 2

By Drucker D.J.

Trends in Endocrinology and Metabolism, Vol. 10, Iss. 4, 1999-05 ,pp. : 153-156

Elsevier

Access to resources Recommend Favorite